Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LTRN 
Lantern Pharma Inc (LTRN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: LTRN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22
1 Year Target Price $22
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.83% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 44.28M USD | Price to earnings Ratio - | 1Y Target Price 22 |
Price to earnings Ratio - | 1Y Target Price 22 | ||
Volume (30-day avg) 2 | Beta 1.47 | 52 Weeks Range 2.55 - 6.12 | Updated Date 09/17/2025 |
52 Weeks Range 2.55 - 6.12 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.78 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -48.35% | Return on Equity (TTM) -88.59% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 25389043 | Price to Sales(TTM) - |
Enterprise Value 25389043 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.21 | Shares Outstanding 10799400 | Shares Floating 8202373 |
Shares Outstanding 10799400 | Shares Floating 8202373 | ||
Percent Insiders 14.09 | Percent Institutions 20.97 |
Upturn AI SWOT
Lantern Pharma Inc
Company Overview
History and Background
Lantern Pharma Inc. was founded in 2013. It leverages artificial intelligence (AI) and machine learning (ML) to rescue, revitalize and de-risk failed or abandoned drug programs. The company's focus is on identifying patients most likely to respond to its therapies by using its AI platform, RADR.
Core Business Areas
- AI-Powered Drug Development: Lantern Pharma utilizes its proprietary AI platform, RADR, to analyze vast amounts of data and identify potential drug candidates and patient populations most likely to benefit from these therapies. This includes biomarkers for drug response.
- Clinical Development Programs: The company focuses on developing targeted cancer therapies in specific patient populations, advancing its drug candidates through clinical trials.
- Companion Diagnostics: Lantern Pharma develops companion diagnostics to identify patients who are most likely to respond to its therapies, maximizing the effectiveness of its treatments.
Leadership and Structure
Panna Sharma serves as President & CEO. The company has a board of directors and a management team overseeing various departments including research and development, clinical operations, and finance.
Top Products and Market Share
Key Offerings
- LP-100 (Onapristone Extended Release): LP-100 is being developed for androgen-independent prostate cancer. It works by modulating androgen receptor activity. Competitors include companies developing other androgen receptor inhibitors, such as ARV-766, and next-generation antiandrogens like Nubeqa and Xtandi. Market share data specifically for LP-100 is not publicly available as it is still in development.
- LP-300: LP-300 is a small molecule therapeutic being developed for never smokers with non-small cell lung cancer. Competitors in this space include other companies developing targeted therapies for specific genetic mutations, as well as checkpoint inhibitors. Market share data specifically for LP-300 is not publicly available as it is still in development.
- RADRu00ae: RADRu00ae is Lantern Pharma's AI platform used for drug development and patient stratification. There are other platforms which also include AI and ML for cancer therapeutics such as those from Recursion Pharma. Market share data specifically for RADR is not publicly available as it's a platform for internal use and collaborations.
Market Dynamics
Industry Overview
The oncology drug development industry is highly competitive and rapidly evolving, with significant investment in targeted therapies, immunotherapies, and personalized medicine. AI and machine learning are increasingly being used to accelerate drug discovery and improve clinical trial outcomes.
Positioning
Lantern Pharma positions itself as a precision oncology company leveraging AI to identify and develop targeted therapies for specific patient populations, particularly in underserved cancer indications. Its competitive advantage lies in its RADR platform and its ability to rescue and revitalize previously abandoned drug programs. It is positioned towards the AI-enabled drug discovery for rare cancers and oncology in general.
Total Addressable Market (TAM)
The global oncology market is estimated to reach hundreds of billions of dollars in the coming years. Lantern Pharma's focus on specific patient populations and targeted therapies positions it to capture a portion of this market, specifically within the AI-driven drug discovery segment.
Upturn SWOT Analysis
Strengths
- Proprietary AI platform (RADR) for drug discovery
- Focus on rescuing and revitalizing abandoned drug programs
- Targeted approach to drug development and personalized medicine
- Experienced management team with expertise in oncology and drug development
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Early-stage clinical development programs
- Reliance on successful execution of clinical trials and regulatory approvals
- Potential competition from larger pharmaceutical companies with more advanced pipelines
Opportunities
- Partnerships with larger pharmaceutical companies to accelerate drug development
- Expansion of RADR platform to new therapeutic areas
- Increasing adoption of AI and machine learning in drug discovery
- Growing demand for personalized cancer therapies
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from other cancer therapies
- Economic downturn affecting investment in biotechnology
Competitors and Market Share
Key Competitors
- ONCT
- CLVS
- MRTX
Competitive Landscape
Lantern Pharma faces significant competition from larger, more established pharmaceutical companies. Its advantage lies in its AI-driven approach and focus on specific patient populations, which allows it to potentially develop more effective and targeted therapies.
Growth Trajectory and Initiatives
Historical Growth: Lantern Pharma's growth has been focused on developing its RADR platform and advancing its drug candidates through preclinical and early clinical development. Revenue growth has been modest as the company is primarily focused on R&D.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals for its drug candidates. Analyst estimates vary widely depending on the perceived likelihood of success for its programs.
Recent Initiatives: Recent initiatives include advancing LP-100 and LP-300 into later-stage clinical trials, expanding the capabilities of the RADR platform, and seeking partnerships with larger pharmaceutical companies.
Summary
Lantern Pharma is an early-stage, AI-driven oncology company with a focus on rescuing and revitalizing drug programs. Its strength lies in its RADR platform and targeted approach, but it faces challenges related to financial resources and clinical trial risk. Success hinges on advancing its drug candidates through clinical development and securing partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Lantern Pharma's SEC Filings
- Company Website
- Analyst Reports
- SEC Edgar database
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Investment in biotechnology companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lantern Pharma Inc
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2020-06-11 | President, CEO & Director Mr. Panna Sharma | ||
Sector Healthcare | Industry Biotechnology | Full time employees 24 | Website https://www.lanternpharma.com |
Full time employees 24 | Website https://www.lanternpharma.com | ||
Lantern Pharma Inc. focuses on the discovery and development of oncology drug. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.